It is a serious threat to the health of women, and the majority of cases are estrogen receptor (ER)‐positive.4 Tamoxifen, a competitive estradiol antagonist, is the first‐line endocrine therapy for (ER)‐positive breast cancer. This evidence concerns the gene ESR1 and breast carcinoma.